PSA Screening Debate, Brain Metastases in HER2 Positive Breast Cancer, and Subcutaneous Immunotherapy
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
PSA Screening Debate, Brain Metastases in HER2 Positive Breast Cancer, and Subcutaneous Immunotherapy
-
ナレーター：
-
著者：
このコンテンツについて
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt breaks down three critical updates in oncology. A new study links declining PSA screening rates to a rise in advanced prostate cancer cases, raising questions about early detection guidelines. We then explore new findings on brain metastases in HER2 positive breast cancer, revealing how patients with CNS only disease have significantly better outcomes than those with extracranial spread. Finally, the FDA has approved subcutaneous nivolumab, offering a faster, more convenient immunotherapy option for multiple cancers. Tune in for the latest insights shaping cancer care!